Eli Lilly and Company $LLY Shares Acquired by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.7% in the 1st quarter, Holdings Channel reports. The firm owned 169,227 shares of the company’s stock after acquiring an additional 13,551 shares during the quarter. Eli Lilly and Company accounts for about 1.6% of Mediolanum International Funds Ltd’s portfolio, making the stock its 9th largest holding. Mediolanum International Funds Ltd’s holdings in Eli Lilly and Company were worth $150,042,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LLY. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at $25,000. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company during the fourth quarter valued at $30,000. Maseco LLP boosted its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. grew its holdings in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,178.01 on Friday. The company has a market cap of $1.11 trillion, a P/E ratio of 41.85, a PEG ratio of 1.48 and a beta of 0.51. The company has a fifty day simple moving average of $1,118.87 and a 200 day simple moving average of $1,036.80. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the company posted $3.34 earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
• Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984
• Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
• Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Rothschild & Co Redburn lifted their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Morgan Stanley raised their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Finally, JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.